^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CYT107

i
Other names: CYT107, Glyco-r-hIL-7, rhIL-7, IL-7, glycosylated rhIL-7, second-generation CYT 99 007, r-hIL-7, CYT-107, glycosylated recombinant human interleukin-7
Associations
Company:
Revimmune
Drug class:
IL-7 agonist
Associations
4ms
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
P2, N=47, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Oct 2024 --> Apr 2024
Trial completion • Trial completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
|
Tecentriq (atezolizumab) • CYT107
7ms
IMPULSE-7: Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (clinicaltrials.gov)
P2, N=8, Terminated, Revimmune | N=12 --> 8 | Trial completion date: Dec 2022 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Dec 2023; non convincing results
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Nontuberculous mycobacteria
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • IL7 (Interleukin 7)
|
CD8 expression
|
CYT107
7ms
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) (clinicaltrials.gov)
P2, N=10, Terminated, Revimmune | Active, not recruiting --> Terminated; POOR ACCRUAL
Trial termination
|
CYT107
11ms
A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma. (ASCO-GU 2024)
This is the first randomized trial of atezo +/- IL-7 (CYT107) in mUC. During the trial, the FDA approval for atezo in mUC was withdrawn, which limited enrollment. However, our results show that the addition of CYT107 to atezo is safe/tolerable, with comparable toxicity profile and efficacy to monotherapy.
Clinical • P2 data • Metastases
|
IL7 (Interleukin 7)
|
Tecentriq (atezolizumab) • CYT107
1year
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
P2, N=47, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Dec 2023 --> Sep 2023
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
Tecentriq (atezolizumab) • CYT107
over1year
A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC) (ESMO 2023)
During the trial, the FDA approval for atezo in mUC was withdrawn, which limited enrollment. However, our results show that the addition of CYT107 to atezo is safe/tolerable, although there was no improvement in clinical outcomes compared to atezo monotherapy.
Clinical • P2 data • Metastases
|
IL7 (Interleukin 7)
|
Tecentriq (atezolizumab) • CYT107
almost2years
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
P2, N=54, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
Tecentriq (atezolizumab) • CYT107
almost2years
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
P2, N=54, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
Tecentriq (atezolizumab) • CYT107
almost3years
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
P2, N=54, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
Tecentriq (atezolizumab) • CYT107
3years
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). (PubMed, J Immunother Cancer)
Treatment with rhIL-7 led to a significant expansion of CD4+ and CD8+ T cells, and CD56 natural killer (NK) cells compared with observation after treatment with sip-T. The rhIL-7 treatment also led to improved antigen-specific humoral and T cell proliferative responses over time as well as to increased expression of activation markers and beneficial cytokines. This is the first study to evaluate the use of rhIL-7 after sip-T in patients with mCRPC and demonstrates encouraging results for combination approaches to augment beneficial immune responses.
Clinical • Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
IFNG expression • IL2 expression
|
Provenge (sipuleucel-T) • CYT107
almost4years
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
P2, N=54, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
Tecentriq (atezolizumab) • CYT107